In today’s rapidly evolving cancer-treatment landscape, academic journals must translate research into reliable evidence that informs clinical decision-making. Therapeutic Advances in Medical Oncology (TAMO) is committed to that mission.
Global cancer incidence continues to rise. There were roughly 20 million new cancer cases worldwide in 2022, and new cases are projected to exceed 35 million by 2050, driven by population aging and lifestyle changes. Rapid, reliable translation of scientific findings into practice is therefore critical.
TAMO publishes clinical trials and real-world evidence with a focus on immunotherapy, targeted therapy and biomarker discovery. The journal prioritizes studies that can directly improve patient outcomes, serving as a bridge between academic advances and clinical care.
Over the past decade TAMO has published research that influenced clinical guidelines and policy documents. A 2022 article, “Reconsidering T component of cancer staging for T3/T4 non-small-cell lung cancer with additional nodule,” was adopted by a Society of Thoracic Surgeons expert consensus in the United States. By re-evaluating T staging in the presence of additional nodules, the study clarified factors affecting surgical feasibility and staging stratification, supporting multidisciplinary discussions and resectability assessments in locally advanced cases.
TAMO promotes clear scientific communication by encouraging plain-language summaries alongside articles. These summaries explain research findings in everyday language for patients, caregivers, healthcare professionals and the public, broadening the societal impact of oncology research.
Manuscripts undergo rigorous handling: initial editorial assessment for ethics and scientific quality, followed by peer review by at least two independent experts. Statistical reviewers are invited when needed. Each submission is managed by the editor and associate editors, all of whom are active researchers with clinical experience, ensuring academic and clinical relevance.
Submissions from Chinese authors have grown in recent years. Chinese researchers have made notable contributions in immunotherapy, targeted drug development, clinical trials, real-world studies and early cancer screening. More than 10 Chinese scholars now serve on the TAMO editorial board. The journal engages the Chinese academic community through webinars and participation in events such as the Annual Meeting of the Chinese Society of Clinical Oncology to support authors and strengthen collaborations.
At the start of TAMO’s 17th year, the journal appointed a new editor based in Shanghai to succeed Georgia Patey. The editor aims to provide direct support to local researchers, helping high-quality work gain broader international visibility. TAMO will continue to welcome submissions from China and foster deeper global collaboration.
TAMO seeks to accelerate the translation of scientific breakthroughs into clinical practice by disseminating high-quality, clinically relevant research that supports evidence-based decision-making and helps address the global burden of cancer.
The author is the editor of Therapeutic Advances in Medical Oncology and senior managing editor at Sage Publishing.
Leave a Reply